Brokerages Expect Unum Therapeutics Inc (NASDAQ:UMRX) Will Post Quarterly Sales of $4.12 Million

Equities analysts forecast that Unum Therapeutics Inc (NASDAQ:UMRX) will report sales of $4.12 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Unum Therapeutics’ earnings, with the lowest sales estimate coming in at $3.83 million and the highest estimate coming in at $4.41 million. Unum Therapeutics posted sales of $3.80 million in the same quarter last year, which suggests a positive year-over-year growth rate of 8.4%. The firm is expected to issue its next earnings results on Thursday, March 26th.

On average, analysts expect that Unum Therapeutics will report full year sales of $10.89 million for the current year, with estimates ranging from $10.00 million to $11.62 million. For the next fiscal year, analysts anticipate that the business will report sales of $15.26 million, with estimates ranging from $5.00 million to $25.33 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.07). The firm had revenue of $1.02 million during the quarter, compared to the consensus estimate of $4.41 million. Unum Therapeutics had a negative net margin of 388.07% and a negative return on equity of 96.07%.

Several research firms recently weighed in on UMRX. Zacks Investment Research upgraded Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Saturday, November 9th. HC Wainwright restated a “buy” rating on shares of Unum Therapeutics in a report on Tuesday, August 13th. Wedbush reduced their target price on Unum Therapeutics from $20.00 to $13.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. They noted that the move was a valuation call. Cowen restated a “hold” rating on shares of Unum Therapeutics in a report on Monday, August 12th. Finally, Morgan Stanley reduced their target price on Unum Therapeutics from $8.00 to $3.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $8.30.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new stake in Unum Therapeutics in the 3rd quarter worth approximately $31,000. Wedbush Securities Inc. acquired a new position in shares of Unum Therapeutics during the third quarter worth approximately $48,000. Susquehanna International Group LLP acquired a new position in shares of Unum Therapeutics during the second quarter worth approximately $62,000. Jane Street Group LLC acquired a new position in shares of Unum Therapeutics during the second quarter worth approximately $132,000. Finally, Paloma Partners Management Co acquired a new position in shares of Unum Therapeutics during the second quarter worth approximately $227,000. Hedge funds and other institutional investors own 43.02% of the company’s stock.

UMRX traded up $0.02 on Monday, hitting $0.69. The company had a trading volume of 370,182 shares, compared to its average volume of 148,198. The company’s fifty day moving average price is $1.06 and its 200 day moving average price is $1.94. Unum Therapeutics has a 1-year low of $0.58 and a 1-year high of $6.64. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.96 and a quick ratio of 1.96. The stock has a market cap of $21.05 million, a price-to-earnings ratio of -0.49 and a beta of 1.01.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Featured Article: Limitations of the P/E Growth ratio

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.